A greater understanding of the genetic, functional, and potential clinical aspects of the activated JAKSTAT3 phenotype and possible PD-L1 expression in BIA-ALCL is necessary, given the recent advancements in JAK inhibitors and antibodies that block the PD1/PD-L1 axis [46,48]. Here, CD274 is linked to anaplastic large cell lymphoma.